INTRODUCTION
As in many other types of cancer, tobacco smoking is suspected to be a risk factor for the development of chronic myeloid leukemia (CML). [1] [2] [3] [4] However, to the best of our knowledge, it is currently not clear whether smoking also is an unfavorable prognostic factor. The few analyses regarding this topic published to date were performed long ago in the era before tyrosine kinase inhibitors, [5] [6] [7] or within the context of stem cell transplantation, 8 and identified smoking as having a harmful impact. Since then, not only smoking habits but also the treatment of patients with CML have changed fundamentally. Thus, the objective of the current study was to investigate the impact of smoking on survival and progression to advanced phases of disease in patients with CML in the era of tyrosine kinase inhibitors.
MATERIALS AND METHODS
Of 1551 patients randomized to the German CML Study IV, 1536 patients were evaluable. Details regarding the study, including a Consolidated Standards Of Reporting Trials (CONSORT) flow chart, have been published previously. [9] [10] [11] The study is registered in ClinicalTrials.gov (ClinicalTrials.gov identifier NCT00055874). The protocol followed the Declaration of Helsinki and was approved by the ethics committee of the Medical Faculty Mannheim and by local ethics committees of the participating centers. Written informed consent was obtained from all patients before they entered the study.
Patients were categorized as smokers and nonsmokers at the time of the diagnosis of CML. Only current smokers were considered as smokers. Information regarding smoking status was available for 1326 patients. The median observation time was 7.0 years (range, 0.1-11.9 years). A total of 163 deaths were observed, and 95 patients experienced disease progression to accelerated phase or blast crisis.
Statistical Analysis
Baseline covariates were compared between smokers and nonsmokers using either the Mann-Whitney U test or the Fisher exact test. Survival times were calculated starting with the date of diagnosis. Patients who were still alive at the time of last follow-up were censored at the date of last observation. For the analysis of disease progression to accelerated phase or blast crisis, death without prior disease progression was considered as a competing event. Cox models were estimated to assess the impact of smoking adjusted for the following covariates: sex, type of treatment center, 12 the prognostic factors of the European Treatment and Outcome Study (EUTOS) long-term survival (ELTS) score 13 (spleen size, thrombocytes, blasts, and age at the time of diagnosis), and comorbidities.
14 For the latter, the age-independent part of the Charlson Comorbidity Index 15 was used. In an additional analysis, an interaction effect between smoking and age also was included. All models were stratified according to randomized treatment. Proportional hazards assumptions were checked as described in Grambsch and Therneau. 16 Due to missing covariates, 34 patients were omitted from the multivariate models. For model selection, the Akaike information criterion was used. All tests performed were 2-sided, and P values < .05 were considered to be statistically significant. All computations were performed using SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC) or R statistical software (version 3.1.2, GNU General Public License; R Foundation, Vienna, Austria).
RESULTS
A total of 261 patients (20%) were smokers. The baseline values of nonsmokers and smokers are described in Table  1 . Nonsmokers and smokers demonstrated significant differences at baseline with regard to hemoglobin (median, 12.1 g/dL for nonsmokers vs 13.0 g/dL for smokers; P<.001), leukocyte count (median, 81.8 3 10 9 /L vs 63.8 3 10 9 /L; P<.001), myelocytes (median, 16% vs 14%; P 5 .026), and age at diagnosis (median, 54 years vs 46 years; P<.001). Smoking was more frequent in men (24%) compared with women (13%). In addition, patients who smoked were found to have a lower educational level, with only 13% of the patients having a higher degree compared with 25% of nonsmokers (P<.001). The distributions of comorbidities, spleen size, platelets, blasts, basophils, and eosinophils were similar for smokers and nonsmokers.
As estimated using the Kaplan-Meier method, the 8-year overall survival (OS) probability of a nonsmoking patient was 87% (95% confidence interval [95% CI], 84%-89%), whereas the 8-year OS probability of a smoker was 83% (95% CI, 78%-88%) (Fig. 1) . In a univariate Cox model, we found a hazard ratio (HR) of 1.38 for the comparison between patients who smoked and those who did not (Table 2 ). In the multivariate model for OS, we identified smoking, increasing age, comorbidities, spleen size, and blasts as adverse prognostic factors (Table 2) . We found a strong negative effect of smoking, with an HR of 2.08 (95% CI, 1.4-3.1; P<.001), which was much stronger than in the univariate model.
As a sensitivity analysis, we included an interaction term between smoking and age. In this model, the disadvantage of smoking was lost with increasing age. As an example, although we found an HR of 8.47 (95% CI, 2.8-25.8; P<.001) for a 16-year-old smoker compared with a 16-year-old nonsmoker, an 80-year-old smoker did not appear to have a higher risk compared with an 80-year-old nonsmoker. The age-dependent HR for smokers compared with nonsmokers is shown in Figure 2 . We did not find any interaction between smoking and the Charlson Comorbidity Index.
Because we wanted to examine the effect of age separately, the ELTS score itself was not used in the model described above. However, when including both the ELTS score and smoking behavior, smoking still was found to have a significant impact (HR, 1.68; P 5 .001).
The 8-year cumulative incidence of disease progression to advanced phase for a nonsmoking patient was 7% (95% CI, 5%-8%), whereas the 8-year cumulative incidence for a smoker was 12% (95% CI, 8%-16%). The cause-specific HR for disease progression to an advanced phase was 1.83 when smokers were compared with nonsmokers (Table 3) . When analyzing the cause-specific risk of disease progression to advanced phases in the same multivariate setting as described above, smoking was found to be the only relevant prognostic factor in addition to blasts, thrombocytes, and spleen size (Table 3) . Patients who smoked were found to have a 2.11-times higher cause-specific HR of disease progression (95% CI, 1.3-3.3; P 5 .001) compared with nonsmokers. Again, both the ELTS score and smoking were found to be significant when the score was included instead of the individual variables.
When analyzing the competing event of death without prior disease progression (data not shown), the results were similar to those described above for OS, although age and comorbidities were found to have a slightly stronger effect, as was expected.
Molecular response rates (eg, major molecular remission) were found to be similar between nonsmokers and smokers (HR, 1.10; 95% CI, 0.9-1.3 [P 5 .259]). Furthermore, we did not find any significant differences between nonsmokers and smokers with regard to adverse events.
With regard to treatment, the frequency of receiving second-generation tyrosine kinase inhibitors was considerably higher in smokers compared with nonsmokers at 8 years: 19% for a nonsmoker compared with 31% for a smoker (P<.001). This might be related to the worse underlying status of patients who smoke, resulting in a higher rate of disease progression and, conversely, making the use of second-generation tyrosine kinase inhibitors necessary. 
DISCUSSION
Smoking is not only suspected to be a risk factor for the development of CML, but also has been found to be highly unfavorable prognostically. The detrimental effects of smoking on normal hematopoiesis are well known. Smoking is the most frequent cause of secondary erythrocytosis, increases leukocyte counts, and promotes platelet aggregation. 17, 18 This result also was found to hold in a multivariate setting when adjusted for, as an example, age, comorbidities, and prognostic score. Therefore, when determining the prognosis of a patient with CML, smoking should be considered to be an important prognostic factor. We found an interaction effect between age and smoking (ie, the unfavorable effect of smoking diminishes in the elderly). We did not find a direct effect of smoking on surrogate endpoints (eg, molecular remission rates).
It already has been observed in other studies concerning the general population that in the oldest age groups, the mortality risk for smokers was similar to or even reduced compared with that of nonsmokers. 19, 20 One potential explanation might be that with ascending age, surviving smokers comprised a selection of increasingly less frail individuals, especially when participating in a clinical trial. Conversely, as other factors become more important in this age group, the relative effect of smoking may diminish.
Smoking often is associated with a lower socioeconomic status and an unhealthy lifestyle. These variables may contribute to the higher mortality of smokers. However, higher cumulative incidences of accelerated-phase disease and blast crises suggest that the lower survival probabilities of smokers are not just the result of smokingrelated mortality (eg, lung and cardiovascular diseases), but that smoking also might affect the biology of the disease.
Smoking has been reported to affect treatment adherence in other diseases, either directly or as an indicator of lower socioeconomic status. [21] [22] [23] However, to our knowledge, no data to date have been published with regard to CML. In the data from the current study, observed molecular remission rates for smokers were nearly as good as those for nonsmokers. Thus, we do not expect poor adherence in the smoker group to be the main reason for the observed differences in survival and disease progression probabilities.
Smoking status was only recorded at baseline. This is a limitation of the current study because it might be of further interest to learn whether patients who stop smoking early during the course of disease experience a good prognosis similar to that of nonsmokers. One may expect that several of the patients who smoked quit after the diagnosis of CML. However, it has been shown that the percentage of patients who stop smoking after a diagnosis of cancer is not higher than in the general population. 24 Because we hardly expect any nonsmokers to start smoking after a diagnosis of CML, we conclude that there is bias just in one direction and that the adverse effects of smoking observed in the current study can be viewed as a certain underestimation. Furthermore, others 25 have shown that for different types of cancer, the cessation of smoking after diagnosis of the tumor has a beneficial effect for the patient and therefore should be promoted.
Cigarette smoking has been found to be responsible for a variety of gene mutations in other types of cancer. 26 It appears possible that a higher frequency of potentially malignant mutations is one reason for the higher risk of disease progression noted in smokers with CML; however, we were not able to test this hypothesis with the data from the current study. Therefore, we would welcome future studies to evaluate both the smoking status as well as the mutation profile.
In addition to the limitations mentioned, there are considerable strengths to the current study. To our knowledge, the current study is the first to demonstrate the unfavorable effects of smoking in patients with CML in a confirmatory way in the tyrosine kinase inhibitor era, based on a large data set with adequate follow-up. Therefore, the results of the current study suggest that patients with CML, especially those aged <60 years, should receive adequate encouragement and support to quit smoking.
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